Liraglutide: 9 published COA source records
302 studies on Liraglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 9 published Liraglutide COA source records from third-party laboratories, covering 4 publicly attributable vendor identities. Across 9 records with positive numeric purity, the arithmetic mean is 99.58%. 0 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 0 positive purity results are below 90%; 0 records report measured amount more than 10% below the label. The latest recorded test date is 2026-09-08. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
Liraglutide: published third-party laboratory evidence
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-09-08. Aggregate calculated: 2026-10-18T15:40:26.318044+00:00. Calculation time is not a laboratory observation date.
Within that total, 1 source record has unresolved vendor identity. It remains in corpus-level lab evidence and is excluded from named-vendor rankings.
Top 3 vendor evidence profiles for Liraglutide
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 4 | 99.66% | 0 of 4 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #2 | 2 | 99.57% | 0 of 2 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #104439 (99.28%) · #105100 (99.87%) · #74549 (99.67%) · #117903 (99.52%) · #90801 (99.619%) · #85047 (99.418%)
Liraglutide studies and clinical research
-
Liraglutide's effect on food intake in obese subjects to be assessed in 6-week RCT
This methodology study, once completed, is important because it will provide specific, quantified data on how **liraglutide** impacts food intake in obese individuals. Understanding the precise mechanisms and magnitud…
-
Semaglutide (Wegovy) to be compared against other anti-obesity drugs for weight loss and quality of life.
A pragmatic clinical study will compare **semaglutide** (Wegovy) to four other anti-obesity medications for weight loss, physical function, and quality of life in US employees.
-
Liraglutide's Efficacy for Blood Glucose Control in Type 2 Diabetes Evaluated in Randomized Phase 3 Trial
A 14-week, randomized Phase 3 trial evaluates **Liraglutide**'s effect on blood glucose in **Type 2 Diabetes** subjects.
-
Liraglutide's metabolic benefits for prediabetes are sex- and reproductive status-dependent in HHTg rats
**Liraglutide's efficacy in prediabetes appears highly dependent on sex and reproductive status**, suggesting a need for personalized treatment approaches. This research highlights that women, particularly those of fe…
-
Liraglutide mitigates LPS-induced osteoclastogenesis and bone loss by downregulating macrophage TNF-α expression
This research expands the therapeutic potential of **Liraglutide** beyond metabolic disorders, suggesting a novel application in inflammatory bone diseases. For peptide users and clinicians, this indicates that GLP-1R…
-
HMB and Liraglutide Synergistically Protect C2C12 Myotubes from Lipotoxic Atrophy via mTOR Signaling
This research highlights a promising synergistic strategy for combating **Type 2 diabetes**-associated sarcopenia, a condition where muscle loss exacerbates metabolic dysfunction. **Combining HMB with Liraglutide coul…
-
Preclinical Evidence Suggests GLP-1RAs Reduce Periodontal Inflammation and Bone Loss via `NF-κB`/`Wnt` Pathways
This review establishes a **biologically plausible hypothesis** for GLP-1RAs in periodontal health, extending their known anti-inflammatory benefits beyond metabolic disease. While current evidence is exclusively prec…
-
Liraglutide's insulin-stimulating effects shift from brain-dependent to direct islet action with advancing metabolic dysfunction
This research provides critical insights into the dynamic mechanisms of **liraglutide**, suggesting that its primary mode of action shifts with the progression of metabolic disease. **This understanding could lead to …
-
Liraglutide's Pancreatic Volume Changes and Hormone Effects to be Investigated by PET-MR
Understanding the nature of **Liraglutide**-induced pancreatic enzyme elevations is critical for patient reassurance and clinical practice. If this study confirms that these elevations are due to adaptive, non-inflamm…
-
Liraglutide weight management utilization patterns investigated in UK primary care database
Understanding the real-world utilization of **liraglutide** for weight management is critical for clinicians, policymakers, and patients. While clinical trials establish efficacy and safety under controlled conditions…
-
Liraglutide Biosimilar Trial Aims to Match Victoza® Efficacy and Safety in Type 2 Diabetes Management
A 26-week trial compared a generic liraglutide injection against brand-name Victoza® for glycemic control, safety, and immunogenicity in type 2 diabetes patients.
-
Liraglutide Switch from Sitagliptin in Type 2 Diabetes Patients Evaluated for Efficacy and Safety
A multinational trial investigated the efficacy and safety of switching from **sitagliptin** to **liraglutide** in **Type 2 Diabetes** patients inadequately controlled on sitagliptin and metformin.
-
Diet-Induced Weight Loss Substudy to Track Knee Osteoarthritis Ultrasound Changes in Obese Patients
This substudy will investigate ultrasound changes in obese knee osteoarthritis patients after an 8-week diet-induced weight loss intervention.
-
Liraglutide Investigated for Reducing Opioid Craving and Relapse in Opioid Use Disorder
Liraglutide is being studied to assess its safety and efficacy in reducing opioid craving and preventing early relapse in patients with opioid use disorder.
-
Liraglutide, not dapagliflozin, normalized renal inflammation and fibrosis in STZ-diabetic rats
This study highlights that **liraglutide offers distinct and superior renoprotective benefits over dapagliflozin in mitigating inflammation and fibrosis in diabetic kidney disease**, even when dapagliflozin is co-admi…
-
Liraglutide reduces PTSD-like anxiety and alters amygdala-hippocampal activity in chemogenetic mouse model
GLP-1 receptor agonism represents a promising, novel therapeutic strategy for **PTSD** and related anxiety disorders, extending beyond its established metabolic benefits. **This research suggests that GLP-1 agonists l…
-
Exercise, with or without liraglutide, improves vascular health and reduces inflammation during weight loss maintenance.
Regular physical activity emerges as a critical component for promoting **vascular health** and reducing **inflammation** in adults with obesity, even when using GLP-1R agonists for weight maintenance. This finding su…
-
Liraglutide pretreatment protects against ethanol-induced gastric ulcers in rats by enhancing mucosal defense and reducing inflammation.
This research highlights a potential novel application for **liraglutide** beyond its established metabolic roles, suggesting it could serve as a prophylactic agent against gastric mucosal damage. For individuals at h…
-
Liraglutide (Victoza®) Post-Marketing Surveillance Initiated to Assess Real-World Safety and Effectiveness
A post-marketing surveillance study in Asia is evaluating the real-world safety and effectiveness of **liraglutide** (Victoza®) in type 2 diabetes patients on non-sulfonylurea antidiabetic agents.
-
Oral Semaglutide Successfully Treats HNF4A MODY Patient, Offering Alternative to Sulfonylureas
This case report highlights a potentially significant shift in the management paradigm for **HNF4A MODY**. Traditionally, `sulfonylureas` are the go-to, but **oral semaglutide** offers a novel, non-sulfonylurea option…
-
Preliminary Study Initiates Assessment of MK-8521 Efficacy and Safety for Type 2 Diabetes
**MK-8521** represents a potential new therapeutic agent for **Type 2 Diabetes** patients whose glycemic control is insufficient with metformin alone. If this preliminary study and subsequent trials demonstrate favora…
-
Liraglutide + canagliflozin combination aimed to prevent HGP rise, improve glycemic control in T2D.
A clinical trial aimed to assess if **liraglutide** plus canagliflozin could prevent compensatory hepatic glucose production (HGP) and enhance glycemic control, weight loss, and blood pressure in Type 2 Diabetes.
-
Liraglutide's influence on gastrointestinal absorption of atorvastatin, lisinopril, griseofulvin, and digoxin investigated
Liraglutide's potential drug-drug interactions with atorvastatin, lisinopril, griseofulvin, and digoxin, and its influence on intragastric pH, are being investigated.
-
East China Observational Study Aims to Identify High-Risk T2D Patients for GLP-1 RA Intervention
This observational study is crucial for refining **Type 2 Diabetes** management by providing real-world insights into **ASCVD** risk stratification and the targeted use of **Glucagon-like peptide-1 receptor agonists**…
-
Liraglutide-potentiated insulin secretion requires Type IIB PKA in mice, regulating KATP and Ca2+ channels.
This study clarifies the specific role of **Type IIB PKA** as a critical mediator for `GLP-1R` agonists like **liraglutide** in enhancing insulin secretion. For peptide users and clinicians, this research highlights t…
-
Adjunctive GLP-1 RAs improve short-term weight loss after bariatric surgery, but not at 12 months
This meta-analysis suggests that **adjunctive GLP-1 RA therapy can provide a short-term boost to weight loss outcomes after bariatric surgery**, particularly within the first 6 months. For individuals experiencing sub…
-
Liraglutide and insulin detemir combination therapy to be investigated for myocardial glucose uptake in T2D
This study aims to clarify how **liraglutide** and **insulin detemir** interact to influence **myocardial glucose uptake** in T2D patients. If synergy is demonstrated, it could lead to **optimized combination therapie…
-
XW003 GLP-1 analogue reduces body weight in obese adults, compares to liraglutide.
XW003, a novel GLP-1 analogue, was evaluated against liraglutide for body weight reduction in obese adults, demonstrating its efficacy.
-
Liraglutide treatment for bile acid malabsorption compared against colesevelam
If **Liraglutide** proves superior or offers a viable alternative to existing treatments like colesevelam for **bile acid malabsorption**, it could significantly **expand therapeutic options for patients suffering fro…
-
Liraglutide safety, tolerability, pharmacokinetics, and pharmacodynamics assessed in obese children aged 7-11 years
A Phase 1 trial aims to evaluate liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in obese children aged 7-11.
-
Planned study to test liraglutide's effect on cognitive function in HIV-associated neurocognitive disorder
Liraglutide will be tested for its effects on cognitive function in HIV-infected, overweight/obese T2DM patients.
-
FIGHT trial investigates GLP-1 agonist therapy for clinical stability in post-Acute Heart Failure Syndrome
The FIGHT trial investigates if subcutaneous GLP-1 agonist therapy improves clinical stability at six months in patients discharged after **Acute Heart Failure Syndrome**.
-
IDegLira Efficacy and Safety to be Evaluated Against Optimized Premixed Insulin in Type 2 Diabetes
This study, once its results are published, will provide crucial evidence for clinicians and patients struggling with **Type 2 Diabetes** management. If **IDegLira** demonstrates superior or non-inferior glycemic cont…
-
Liraglutide study to assess weight reduction and safety in pubertal adolescents with obesity
If this trial demonstrates positive results, **liraglutide could become a crucial pharmacological tool for treating adolescent obesity**, offering a much-needed option beyond lifestyle interventions alone. Currently, …
-
GLP-1 receptor agonists significantly mitigate metabolic side effects of clozapine and olanzapine therapy in psychiatric patients.
This review underscores that **GLP-1 receptor agonists offer a critical strategy to manage severe metabolic complications** in patients on essential antipsychotics, potentially improving long-term health outcomes and …
-
Liraglutide combination with rosiglitazone and metformin evaluated for glycemic control in Type 2 Diabetes
While specific results from this trial are not available in the provided abstract, the investigation of **Liraglutide** in a triple combination with rosiglitazone and metformin highlights a strategy for intensifying *…
-
Insulin glargine aims for superior HbA1c control vs. liraglutide in Type 2 diabetes after oral agent failure
The comparative effectiveness of **insulin glargine** versus **liraglutide** in T2D patients who have failed oral agents is a critical clinical question. If one agent demonstrates clear superiority in achieving glycem…
-
Liraglutide's Glycemic Control Efficacy as Metformin Add-on Investigated Against Other Oral Antidiabetics in Type 2 Diabetes
**Establishing the optimal sequence and combination of therapies for Type 2 Diabetes is critical for improving patient outcomes.** If this trial's full results demonstrate superior or non-inferior glycemic control wit…
-
MEDI0382 Phase 2 trial to assess hepatic glycogen metabolism in overweight/obese T2DM patients
If successful, this study could establish **MEDI0382 as a promising therapeutic candidate for T2DM**, particularly for patients struggling with associated hepatic complications like NAFLD. By targeting hepatic glycoge…
-
Liraglutide's Effect on Left Ventricular Function in Chronic Heart Failure Patients Under Investigation
Understanding **Liraglutide's** impact on left ventricular function in **chronic heart failure (CHF)** patients, particularly those with co-existing **Type 2 Diabetes**, could significantly inform future treatment str…
-
Liraglutide attenuates nicotine reward in mice by downregulating hypothalamic prepro-orexin and NTS prepro-glucagon
This study provides compelling preclinical evidence that **liraglutide could be a novel therapeutic strategy for nicotine addiction**, potentially offering a new avenue for smoking cessation. By targeting the **orexin…
-
Liraglutide induces acute hepatocellular injury with positive rechallenge in a 58-year-old woman
This case underscores that **liraglutide, despite its general safety, can rarely cause severe idiosyncratic hepatocellular injury**. For clinicians and patients using `GLP-1 RA`s, vigilance for unexplained elevations …
-
Liraglutide Investigated for Reducing Dietary Lipid-Induced Insulin Resistance in Humans
If **Liraglutide** were shown to effectively reduce dietary lipid-induced **insulin resistance**, it would significantly broaden its therapeutic utility beyond current glycemic control. This could lead to **improved m…
-
CinnaGen-liraglutide Phase III trial compares efficacy and safety against Victoza® in Type II diabetes
If CinnaGen-liraglutide demonstrates non-inferiority to Victoza®, it could significantly impact the **treatment landscape for Type II diabetes**. The introduction of a biosimilar or bioequivalent liraglutide could lea…
-
Liraglutide as Add-on to Insulin Pump Therapy Investigated for Type 1 Diabetes Glycemic Control
If this trial demonstrates positive outcomes, **Liraglutide could become a valuable adjunctive therapy for overweight Type 1 Diabetes patients on insulin pumps**, potentially improving glycemic control and reducing in…
-
Trial initiated to compare insulin degludec/liraglutide, insulin degludec, and liraglutide efficacy in Chinese T2DM patients.
If successful, this trial could establish **insulin degludec/liraglutide** as a superior treatment option for Chinese **Type 2 Diabetes Mellitus** patients whose `HbA1c` levels are not adequately managed by OADs alone…
-
Liraglutide-depot safety, tolerability, and pharmacokinetics investigated in healthy subjects
A Phase 1 trial assessed the safety, tolerability, and pharmacokinetics of **Liraglutide-depot** in healthy subjects in the USA.
-
Liraglutide Expected to Improve Glycemic Control and Preserve Beta-Cells in Uncontrolled Type 1 Diabetes
Liraglutide is hypothesized to improve glycemic control in uncontrolled type 1 diabetic patients, with an expected **1% reduction** in `HbA1c` from baseline.
-
RISE Study to Evaluate Liraglutide, Metformin, and Insulin Glargine for Durable Beta-Cell Function Recovery in Prediabetes and Early Type 2 Diabetes
This study is pivotal for understanding whether current glucose-lowering strategies can offer more than symptomatic control, potentially leading to disease modification in **prediabetes and early type 2 diabetes**. If…
Research tools
Free, no account — handy when you're working with Liraglutide.
